BIOCAD is one of Russia's leading innovative biopharmaceutical companies, combining a world-class research and development center, ultra-modern pharmaceutical and biotechnological manufacturing facilities, and an international-standard preclinical and clinical research infrastructure. The company is dedicated to the development, manufacturing, and marketing of original and biosimilar medicines, primarily in the fields of oncology, autoimmune diseases, and infectious diseases. BIOCAD's mission is to improve and prolong human lives by providing effective, safe, and affordable treatments. They have a strong focus on import substitution and export development, aiming to make advanced therapies accessible globally.
Serves as the central hub for research and development, advanced manufacturing of biotechnological and pharmaceutical products, quality control, and corporate strategic operations.
State-of-the-art R&D laboratories, modern GMP-compliant manufacturing facilities, advanced infrastructure for cell and gene therapy development. The campus is designed to foster innovation and collaboration.
A dynamic and science-driven environment focused on innovation, collaboration, and continuous learning. Employees are often involved in cutting-edge research and development projects.
The Strelna campus is a cornerstone of BIOCAD's operations, enabling the full cycle of drug development from idea to commercial product, and representing a significant investment in Russia's biotech infrastructure.
BIOCAD supports a range of global functions including international business development, clinical trial management across multiple regions, product registration, marketing and sales in CIS countries, Southeast Asia, Latin America, the Middle East, and North Africa. The company actively seeks partnerships to expand its reach for its innovative and biosimilar drugs, with representative offices and operations in countries like Belarus, Kazakhstan, Vietnam, UAE, China, and Brazil.
Svyazi str., 34, lit. A, settlement Strelna
St. Petersburg
N/A (Federal city)
Russia
Address: Smolenskaya pl., 3, Smolensky Passage, Moscow, 121099, Russia
To drive market penetration and stakeholder engagement within Russia's largest metropolitan area and federal administrative center.
Address: BIOCAD DMCC, Unit No: 3680, DMCC Business Centre, Level No 1, Jewellery & Gemplex 3, Dubai, United Arab Emirates
To expand BIOCAD's presence and product portfolio in the growing MENA pharmaceutical market.
Address: BIOCAD (Shanghai) Pharmaceutical Co., Ltd., Room 207, Building 5, No.55 Chuanhe Road, Pudong New Area, Shanghai, China
To tap into the large Chinese pharmaceutical market and leverage China as a hub for regional expansion and research collaboration.
Address: 220005, Minsk, ave. Nezavisimosti 58V, office 403
To ensure availability of BIOCAD's innovative and biosimilar medicines in Belarus and support local healthcare needs.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, BIOCAD' leadership includes:
BIOCAD has been backed by several prominent investors over the years, including:
Information on specific executive hires or exits at BIOCAD in the last 12 months is not widely publicized. The company maintains a stable core leadership team focused on long-term strategic goals. Any significant changes are typically announced via official press releases.
Discover the tools BIOCAD uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
BIOCAD's email format commonly follows a [lastname]_[first_initial]@biocad.ru pattern for its Russian operations. For international communications or specific departments, variations might exist, potentially using the biocadglobal.com domain.
[lastname]_[f]@biocad.ru
Format
morozov_d@biocad.ru
Example
85%
Success rate
BIOCAD Press Release • May 23, 2024
BIOCAD shared results from clinical studies of Divaras® (INN: seniprutug) for ankylosing spondylitis at the XXXI Russian National Congress 'Man and Medicine.' The data confirmed the drug's high efficacy and favorable safety profile in long-term use....more
BIOCAD Press Release • April 18, 2024
BIOCAD and the Ministry of Health of Nicaragua signed a memorandum of cooperation aimed at improving the provision of medicines to the population of Nicaragua. The agreement focuses on expanding access to modern therapies for cancer and autoimmune diseases....more
BIOCAD Press Release • February 29, 2024
BIOCAD has obtained marketing authorization for its drug Gladcentri® (INN: eculizumab) in Saudi Arabia. This monoclonal antibody is used for treating paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome, marking a significant step in BIOCAD's expansion in the MENA region....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including BIOCAD, are just a search away.